Trial Profile
A phase I, open label study investigating pharmacokinetics, safety and tolerability of single and multiple oral doses of Odanacatib in Chinese and Non-Chinese Postmenopausal Women
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Mar 2018
Price :
$35
*
At a glance
- Drugs Odanacatib (Primary)
- Indications Osteoporosis
- Focus Adverse reactions; Pharmacokinetics
- 01 Mar 2018 New trial record